"We Envision Growth Strategies Most Suited
to Your Business"

Prothrombin Complex Concentrate Market to Rise at 10.6% CAGR by 2027; Increasing Utilization of Plasma Products in Hospitals to Propel Market Growth

July 22, 2020 | Healthcare

The global prothrombin complex concentrate (PCC) market size is projected to reach USD 1,604.9 million by 2027 on account of growing preference for 4-factor PCC among patients, observes Fortune Business Insights™ in its report, titled “Prothrombin Complex Concentrate (PCC) Market Size, Share & COVID-19 Impact Analysis, By Product (3-factor PCC and 4-factor PCC), By Application (Acquired Coagulation Factor Deficiency and Congenital Coagulation Factor Deficiency), By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics and Others), and Regional Forecast, 2020-2027”. As per the report, the market value stood at USD 695.3 million in 2019 and is expected to exhibit a CAGR of 10.6% from 2020 to 2027.


The PCC market growth is expected to accelerate during 2020 owing to the outbreak of the COVID-19 pandemic. Pharmaceutical companies are reporting a swift change in consumer towards plasma-derived therapies, prompting these companies to ramp up their production and supply capacity of these treatments.


Takeda Successfully Acquires Shire plc, Becomes Global Leader in Biopharmaceuticals


Strategic acquisitions have become commonplace in the market for prothrombin complex concentrate. Leading this trend is the Japanese pharmaceutical bigwig, Takeda Pharmaceutical, which completed its takeover of the US-based biopharmaceutical specialist, Shire plc, in January 2019. The acquisition positions Takeda as global giant in biopharmaceutical research, especially in the domain of rare diseases. Furthermore, this move enlarges the company’s footprint in North America as well as in East Asia, allowing it to market and distribute its innovative PCC therapies in these regions. Lastly, the takeover augments Takeda’s R&D capabilities in rare diseases, neuroscience, gastroenterology, and oncology.


To get a detailed report summary and research scope of this market, click here:


https://www.fortunebusinessinsights.com/industry-reports/prothrombin-complex-concentrate-pcc-market-100102


Adverse Side Effects Associated with Warfarin to Stoke PCC Adoption


Warfarin is a commonly prescribed medication to inhibit formation of blood clots that can potentially lead to stroke or heart attack. However, imbalanced, unnecessary, and excessive prescription or consumption of this drug can trigger internal bleeding and can, in turn, further hamper the natural blood clotting process. Some of the major side effects of warfarin include joint pain and swelling, unexplained bruising on the body, vomiting blood, unusually heavy menstrual bleeding, and severe headache along with vision dysfunction. Prothrombin complex concentrate is a plasma-based therapy indicated to prevent bleeding in patients having impaired blood clotting mechanisms. This therapy has proven to be highly efficient in managing warfarin-induced bleeding in patients and as warfarin prescriptions increase, the demand for PCC is likely to rise commensurately.


Key Players to Engage in Tactical Takeovers to Expand Market Footprint


Some of the major players in the market for prothrombin complex concentrate, which are extremely limited in number, are increasingly entering into takeover deals to deepen their foothold regionally as well as globally. Improved access to new regions, along with the opportunities to establish strong distribution and sales network, is prompting these companies to massively invest in acquisition ventures. Moreover, the on-going COVID-19 pandemic is proving lucrative for the market players as the uptake of plasma-based therapies is skyrocketing across the globe.    


Industry Development:



  • January 2018: China Biologic Products Holdings acquired 80% equity in Tianxinfu (Beijing) Medical Appliance Co., Ltd. from a leading Chinese medical device company called PW Medtech Group. China Biologics, through this acquisition, intends to tap the speedily developing regenerative medical bio-material industry in China, utilizing Tianxinfu’s extensive sales network and marketing experience.


List of Companies Profiled in this Market Report:



  • China Biologic Products Holdings, Inc.

  • Sanquin

  • CSL Behring

  • Takeda Pharmaceutical Company Limited

  • Kedrion S.p.A

  • Octopharma AG

  • Grifols, S.A.


Further Report Findings:



  • The congenital coagulation factor deficiency segment is expected to display healthy growth in the near future on account of active regulatory support to innovative therapies indicated for severe blood disorders such as Hemophilia B.

  • Increasing sales of Kcentra in the US is anticipated to fuel the market in North America and establish the region’s dominance in the prothrombin complex concentrate market share during the forecast period. In 2019, the region’s market size was at USD 305.9 million.

  • The market in Latin America and the Middle East & Africa is expected to grow steadily owing to the rising incidence of bleeding disorders and improved spending on healthcare.


Table of Segmentation:











































 ATTRIBUTE



  DETAILS



Study Period



   2016-2027



Base Year



  2019



Forecast Period



  2020-2027



Historical Period



  2016-2018



Unit



Value (USD million)



Segmentation



By Product Type



  • 3-factor PCC

  • 4-factor PCC



By Application



  • Acquired Coagulation Factor Deficiency

  • Congenital Coagulation Factor Deficiency



By End User



  • Hospital & Ambulatory Surgical Centers

  • Specialty Clinics

  • Others



By Geography



  • North America (the U.S. and Canada)

  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)

  • Latin America (Brazil, Mexico, and Rest of Latin America)

  • The Middle East& Africa (South Africa, GCC, and Rest of the Middle East & Africa)


Prothrombin Complex Concentrate (PCC) Market
  • PDF
  • 2019
  • 2016-2018
  • 158

    CHOOSE LICENSE TYPE

  • 4850
    5850
    6850

Our Clients

Bain & Company
BASF
Asahi
Kpmg
Airbus
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X